Creative Planning
STML

Creative Planning’s Stemline Therapeutics, Inc. STML Stock Holding History

Creative Planning’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,150
Closed -$10K – 4942
2017
Q1 		$10K Hold
1,150
– – ﹤0.01% 3619
2016
Q4 		$12K Hold
1,150
– – ﹤0.01% 3453
2016
Q3 		$12K Buy
+1,150
New +$9.35K ﹤0.01% 3428
2016
Q2 		– Sell
-300
Closed -$1K – 4598
2016
Q1 		$1K Buy
+300
New +$1.47K ﹤0.01% 4215
2014
Q3 		– Sell
-20
Closed – – 4223
2014
Q2 		$0 Hold
20
– – ﹤0.01% 4033
2014
Q1 		$0 Buy
+20
New +$485 ﹤0.01% 3820

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Creative Planning's STML Position: Q2 2017 in Review

Creative Planning sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 1,150 shares — an estimated $10K sold.

Creative Planning first reported a position in STML in Q1 2014 and held it in 6 quarters. The position peaked at $12K in Q4 2016. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

  • Creative Planning reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Creative Planning sold 1,150 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $10K.
  • Creative Planning first reported a position in Stemline Therapeutics, Inc. in Q1 2014 and held it in 6 quarters.
  • Creative Planning's Stemline Therapeutics, Inc. position peaked at $12K in Q4 2016.
  • 70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on Creative Planning's 13F filing for Q2 2017, filed 12 Jul 2017.